ROCKVILLE, Md., May 16, 2023 /PRNewswire/ -- REGENXBIO Inc. today announced that preclinical research in Mucopolysaccharidosis type IVA (MPS IVA), also known as Morquio syndrome, was selected for ...
REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results